Ten-Year Follow-up Clinical Outcomes and the Role of Adjuvant Chemotherapy in HER2-Positive Patients with Microinvasive Breast Cancer
A clinically meaningful proportion of HER2-positive MIBC patients experience IBCFS events with long-term follow-up. Adjuvant chemotherapy did not improve survival, potentially due to the use of an outdated, ineffective regimen. The role of modern adjuvant regimens, particularly those incorporating HER2-targeted therapy, warrants further exploration.
Authors
- Hyehyun Jeong (ORCID: https://orcid.org/0000-0001-7277-6463)
- Jin‐Hee Ahn (ORCID: https://orcid.org/0000-0003-4994-9965)
- Sung‐Bae Kim (ORCID: https://orcid.org/0000-0001-5588-8332)
- Byung Ho Son (ORCID: https://orcid.org/0000-0002-6757-0388)
- Il Yong Chung (ORCID: https://orcid.org/0000-0001-5271-8530)
- Kyung Hae Jung (ORCID: https://orcid.org/0000-0002-1580-7224)
- Hee Jeong Kim (ORCID: https://orcid.org/0000-0002-4509-953X)
- Yeokyeong Shin (ORCID: https://orcid.org/0009-0000-0403-2091)
- Ji Sun Kim
- Soo Young Lee (ORCID: https://orcid.org/0000-0002-5354-3135)
- Jae Ho Jeong (ORCID: https://orcid.org/0000-0002-8749-2612)
- Gyungyub Gong
- BeomSeok Ko
- Jong Won Lee
- Sae Byul Lee
- Hee Jin Lee
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Inha University Hospital (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-03-05
- DOI
- https://doi.org/10.4143/crt.2024.1120
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.05